sapogenins and Sepsis

sapogenins has been researched along with Sepsis* in 1 studies

Other Studies

1 other study(ies) available for sapogenins and Sepsis

ArticleYear
Ruscogenin attenuates sepsis-induced acute lung injury and pulmonary endothelial barrier dysfunction via TLR4/Src/p120-catenin/VE-cadherin signalling pathway.
    The Journal of pharmacy and pharmacology, 2021, Jun-08, Volume: 73, Issue:7

    Sepsis-associated acute lung injury (ALI) occurs with the highest morbidity and carries the highest mortality rates among the pathogenies of ALI. Ruscogenin (RUS) has been found to exhibit anti-inflammation property and rescue lipopolysaccharide-induced ALI, but little is known about its role in sepsis-triggered ALI. The aim of this study was to investigate the potential role of RUS in sepsis-induced ALI and the probable mechanism.. Mice model of cecal ligation and puncture (CLP) was replicated, and three doses of RUS (0.01, 0.03 and 0.1 mg/kg) were administrated 1 h before CLP surgeries.. RUS significantly extended the survival time and attenuated the lung pathological injury, oedema and vascular leakage in sepsis-induced ALI mice. RUS efficiently decreased the level of MPO in lung tissue and the WBC, NEU counts in BALF. In addition, RUS rescued the expression of VE-cadherin and p120-catenin and suppressed the TLR4/Src signalling in lung tissue.. RUS attenuated sepsis-induced ALI via protecting pulmonary endothelial barrier and regulating TLR4/Src/p120-catenin/VE-cadherin signalling pathway.

    Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Antigens, CD; Blood-Air Barrier; Cadherins; Catenins; Delta Catenin; Disease Models, Animal; Mice; Protective Agents; Sapogenins; Sepsis; Signal Transduction; Spirostans; Toll-Like Receptor 4; Treatment Outcome

2021